Steven Cheng 程翔

🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely enjoyed medical advances years before their American counterparts. Through a generation of congressional actions, investments in expertise and hiring, and careful policymaking, we built the FDA into the most efficient, forward-leaning drug regulatory agency in the world—and established the U.S. as the global center of biopharmaceutical innovation. Today, the cumulative barrage on that drug-discovery enterprise, threatens to swiftly bring back those frustrating delays for American consumers, particularly affecting rare diseases and areas of significant unmet medical need.